Drug
Ak117
Ak117: highest development phase Phase 1/2, developed by Akeso. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK117 NCT04980885 | Phase 1/2 | Acute Myeloid Leukemia |
| AK117 NCT04349969 | Phase 1 | Neoplasms Malignant |
Latest
No recent events.
Follow Ak117 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.